CDK6 and glioma: In addition to the miRNA delivery in vitro, we also found that BM-MSCs that were administered ipsilaterally were able to peripherally penetrate the U87-derived xenografts, deliver the Cy3-miR-124 to nearby glioma cells and downregulate the expression of the miR-124 target gene, CDK6.